Skip to main content
Skip to navigation

MU Signs Agreement With

Global PET Imaging

MU Signs Agreement

Global PET Imaging LLC would utilize the expertise of the MU Research Reactor (MURR®) and nuclear medicine scientists to produce active ingredient for diagnostic drug

Hoping to Help Heart Attack Patients, MU Signs Agreement With Global PET

Story Contact: Christian Basi, BasiC@missouri.edu, 573-882-4430                                                                                         

COLUMBIA, Mo. ­— Following a heart attack, many patients consult with their doctors about the necessity of heart bypass surgery. However, the active ingredient for a test that helps determine the need for surgery could be in short supply in the near future. Now, an agreement signed by officials from the University of Missouri and Global PET Imaging LLC (GPI) could lead to a solution to that shortage.

In order to determine the condition of the heart and blood flow after a heart attack, doctors usually prescribe two tests or scans of the heart and surrounding area. One of those scans uses a radioisotope known as Rubidium-82, but the supply of the isotope is limited because few facilities have the ability to make it. Today, officials from MU and GPI announced the signing of a “Letter of Intent” to create a processing facility for this isotope near the MU campus, taking advantage of expertise at the nation’s largest university research reactor.

“The market for rubidium is growing much faster than the supply, and we must find a way to increase production for this isotope that could save many lives,” said Steve Wyatt, MU vice provost for economic development. “We have researchers and experts in nuclear medicine here on this campus that also is home to the nation’s most powerful university research reactor. We already have experience in producing many other radioisotopes for medical use, and we’re looking forward to the future of this partnership.”

Read the rest at the MU News Bureau >>